BCAB BioAtla, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1826892 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY63.6%
TTM EPS YoY177.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-277.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets4,031.1%
Debt / equity—
Current ratio0.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.62x
Accruals ratio-105.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.41M | $3.34M | $4.58M | $8.00M | $9.54M | $13.68M | $12.36M | $11.65M |
| SG&A expense | $2.34M | $2.93M | $4.73M | $3.26M | $4.25M | $4.96M | $5.26M | $4.59M |
| Operating income | -$8.36M | $227,000 | -$9.31M | -$9.26M | -$13.79M | -$18.65M | -$17.61M | -$16.24M |
| Net income | -$7.90M | $452,000 | -$6.34M | -$9.78M | -$15.78M | -$18.71M | -$15.33M | -$14.88M |
| EBITDA | -$8.36M | $227,000 | -$9.19M | -$9.24M | -$13.73M | -$18.53M | -$17.43M | -$16.02M |
| EPS (basic) | -4.74 | 0.27 | -4.22 | — | -13.43 | -15.99 | -13.16 | — |
| EPS (diluted) | -4.74 | 0.27 | -4.22 | — | -13.43 | -15.99 | -13.16 | — |
| Weighted avg. shares (diluted) | 1.67M | 1.66M | 1.50M | — | 1.17M | 1.17M | 1.16M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $576,000 | $1.54M | $1.96M | $7.12M | $8.32M | $18.21M | $32.36M | $49.05M |
| Receivables | $0 | $2.00M | — | $0 | — | — | — | — |
| Current assets | $946,000 | $4.26M | $3.09M | $8.01M | $9.67M | $20.61M | $37.54M | $51.23M |
| PP&E, net | $0 | $0 | $0 | $120,000 | $324,000 | $380,000 | $495,000 | $678,000 |
| Total assets | $1.11M | $9.51M | $8.57M | $13.83M | $15.91M | $27.13M | $38.29M | $52.42M |
| Current liabilities | $20.69M | $21.02M | $20.69M | $21.92M | $17.98M | $16.60M | $16.01M | $14.54M |
| Total liabilities | $44.70M | $45.74M | $45.88M | $50.02M | $47.15M | $43.87M | $37.74M | $38.16M |
| Shareholders' equity | -$43.60M | -$36.24M | -$37.31M | -$36.19M | -$31.24M | -$16.75M | $547,000 | $14.27M |
| Shares outstanding | 1.67M | 1.66M | 1.66M | 1.27M | 58.79M | 58.72M | 58.40M | 58.10M |
| Cash flow statement | ||||||||
| Operating cash flow | -$967,000 | -$419,000 | -$5.27M | -$7.92M | -$9.88M | -$14.12M | -$16.29M | -$16.78M |
| Investing cash flow | — | — | — | — | — | — | $0 | $0 |
| Financing cash flow | -$1,000 | $2,000 | $110,000 | $6.71M | -$6,000 | -$36,000 | -$395,000 | $9.31M |
| Depreciation & amortization | $0 | $0 | $120,000 | $19,000 | $56,000 | $115,000 | $183,000 | $228,000 |
| Stock-based compensation | $538,000 | $619,000 | $956,000 | $1.12M | $1.29M | $1.38M | $1.65M | $1.93M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.